BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 66 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $63,286 | -23.0% | 22,051 | +35.5% | 0.00% | – |
Q2 2023 | $82,158 | +55.4% | 16,269 | -41.8% | 0.00% | – |
Q1 2023 | $52,871 | -5.9% | 27,974 | -10.3% | 0.00% | – |
Q4 2022 | $56,164 | -85.5% | 31,202 | -86.4% | 0.00% | – |
Q3 2022 | $387,000 | -70.7% | 229,189 | -57.3% | 0.00% | – |
Q2 2022 | $1,319,000 | -3.4% | 536,220 | +8.7% | 0.00% | – |
Q1 2022 | $1,366,000 | -66.9% | 493,362 | -36.3% | 0.00% | -100.0% |
Q4 2021 | $4,127,000 | -35.9% | 773,936 | +1.7% | 0.00% | 0.0% |
Q3 2021 | $6,439,000 | -12.1% | 761,091 | +26.6% | 0.00% | 0.0% |
Q2 2021 | $7,327,000 | +2255.9% | 601,020 | +4599.9% | 0.00% | – |
Q1 2021 | $311,000 | -91.3% | 12,788 | -88.5% | 0.00% | -100.0% |
Q4 2020 | $3,578,000 | +1292.2% | 111,661 | +1212.0% | 0.00% | – |
Q3 2020 | $257,000 | +59.6% | 8,511 | +123.0% | 0.00% | – |
Q2 2020 | $161,000 | +360.0% | 3,816 | +170.6% | 0.00% | – |
Q1 2020 | $35,000 | – | 1,410 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |